<DOC>
	<DOCNO>NCT02327182</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy 2 fix dose MT-4666 administer daily 52 week without receive concomitant acetylcholinesterase inhibitor ( AChEIs ) , patient mild moderate Alzheimer 's Disease ( AD ) .</brief_summary>
	<brief_title>Safety Study MT-4666 Subjects With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Probable Alzheimer 's disease consistent National Institute Aging Alzheimer 's Association Criteria Diagnosis Alzheimer 's Disease ( McKhann et al . 2011 ) . MMSE score ≥ 14 ≤ 24 screen ≥ 12 ≤ 26 baseline . Modified Hachinski Ischemic Score ( mHIS ) ≤ 4 screen Appropriate caregiver available Subject living home facility require continuous ( 24hour ) nursing care . Diagnosis disease may cause dementia Diagnosis major depressive disorder define Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) within last five year History current diagnosis psychosis History myocardial infarction unstable angina within six month screen History cerebrovascular disorder within 18 month screen complication hepatic disorder renal dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>MT-4666</keyword>
	<keyword>α7 nicotinic acetylcholine receptor agonist</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Cognitive function</keyword>
	<keyword>Dementia</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>